Vimarsana
Biggest News Aggregation in the World

Page 3 - Spherix Global News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Spherix Global. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Spherix Global Today - Breaking & Trending Today

Sanofi (SNY) Q2 2023 Earnings Call Transcript - Vimarsana News

Sanofi (SNY) Q2 2023 Earnings Call Transcript

SNY earnings call for the period ending June 30, 2023.

Source: fool.com
5 numbers making gastroenterologists nervous - Vimarsana News

5 numbers making gastroenterologists nervous

Here are five statistics gastroenterology and healthcare leaders should keep an eye on.

Fecal Microbiota Transplant Therapy May Change Paradigm of C. Difficile Treatment - Vimarsana News

Fecal Microbiota Transplant Therapy May Change Paradigm of C. Difficile Treatment

Spherix Global Insights estimates that SER-109 (Seres Therapeutics; Aimmune) will be able to challenge fecal microbiota, live-jslm in C. difficile treatment.

Half of US neurologists expect to test Briumvi in the next 6 months | Recently approved Briumvi is 3rd CD20 inhibitor available for relapsing MS - Vimarsana News

Half of US neurologists expect to test Briumvi in the next 6 months | Recently approved Briumvi is 3rd CD20 inhibitor available for relapsing MS

Most neurologists in the U.S. are aware of the recent approval of Briumvi for relapsing forms of MS, according to a market research firm.

Related Topics:
Spherix Global
Can BMS' Zeposia Cement a Defensible Market Position in Ulcerative Colitis Ahead of Pfizer's Potential Rival S1P treatment, etrasimod? According to Spherix Global Insights - Vimarsana News

Can BMS' Zeposia Cement a Defensible Market Position in Ulcerative Colitis Ahead of Pfizer's Potential Rival S1P treatment, etrasimod? According to Spherix Global Insights

/PRNewswire/ -- Analysis from Spherix Global Insights quarterly market tracker, RealTime Dynamix™: Ulcerative Colitis, reveals that at twenty (20) months after...